Schedule 1 Therapeutics Inc.

Chicago, IL

UEI
TV68WM7PHYW3
CAGE
8DJ23
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
222 W Merchandise Mart Plaza #1230, Chicago, IL 60654, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Optimization of cannabinoids for development as FDA-approved migraine therapeutics R44DA051309 National Institute on Drug Abuse (NIH) $2,883,639
Optimization of cannabinoids for development as FDA-approved migraine therapeutics R41DA051309 National Institute on Drug Abuse (NIH) $299,510

Quick answers

Is Schedule 1 Therapeutics Inc. registered in SAM.gov?

Yes. Schedule 1 Therapeutics Inc.'s SAM.gov registration is active through April 6, 2027.

What is Schedule 1 Therapeutics Inc.'s most recent federal award?

Schedule 1 Therapeutics Inc.'s most recent federal grant award is Optimization of cannabinoids for development as FDA-approved migraine therapeutics (R44DA051309), from National Institute on Drug Abuse (NIH), on September 30, 2020.

On GovTribe

See Schedule 1 Therapeutics Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login